Reach Us +1-217-403-9671
The Interaction Between Clopidogrel And Proton Pump Inhibitors In Japanese Patients | 8306
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

The interaction between clopidogrel and proton pump inhibitors in Japanese patients

International Conference and Exhibiton on Pharmaceutical Regulatory Affairs

Takeo Yasu

ScientificTracks Abstracts: JBB

DOI: 10.4172/0975-0851.1000107

C lopidogrel is an antiplatelet medicine that is used to prevent problems with blood clots such as heart attacks or strokes. Clopidogrel is a pro-drug, which needs to be activated through the action of cytochrome P450 (CYP) 1A2, 2B6, 2C9, 2C19, and 3A. Proton pump inhibitors (PPI) are frequently used to prevent upper gastrointestinal bleeding. However, previous studies have reported that concomitant use of clopidogrel and PPI is associated with an increase in the number of major adverse cardiovascular events (MACE) and a decrease in the antiplatelet eff ect of clopidogrel, which is attributable to the drug interaction involving cytochrome CYP 2C19. CYP2C19 polymorphism has been suggested as the cause of clopidogrel resistance and aff ects clinical outcomes. In fact, several studies have shown the possibility that PPI, especially omeprazole, might diminish the antiplatelet eff ects of clopidogrel through inhibition of CYP2C19. On the other hand, there are also confl icting data that the interaction between clopidogrel and PPI had no eff ect on clinical outcome. Whether a ?clinically meaningful? interaction exists between PPIs and dual antiplatelet therapy is uncertain. Th e frequency of CYP2C19 poor metabolizer in Japan is about 20%, which is higher than that in Western countries. Th erefore, we hypothesized that Japanese patients receiving clopidogrel and PPI might be at increased risk of MACE. Th e objectives of this study are to investigate whether rabeprazole reduces the risk of GI bleeding, and increases the incidence of MACE during dual- antiplatelet therapy aft er drug-eluting stent implantation in Japanese patients
Takeo Yasu graduated from School of Pharmacy, Showa University in 2002. He did his MSc at department of Biochemical Toxicology, School of Pharmacy, Showa University in 2004. Presently working at Department of Pharmacy, Shonan Kamakura General Hospital, Japan.